Premium
Peramivir for the treatment of uncomplicated influenza
Author(s) -
Chaplin Steve
Publication year - 2019
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.1734
Subject(s) - medicine , adverse effect , intensive care medicine
Peramivir (Alpivab) is an intravenous antiviral medicine licensed for the treatment of uncomplicated influenza in adults and children from the age of two years. This article examines its efficacy and adverse effects.